Menus Subscribe Search

Follow us


Genes Are Us

HIV

(Photo: Sebastian Kaulitzki/Shutterstock)

Why the HIV Vaccine Is Not a Pipe Dream

• January 10, 2014 • 8:00 AM

(Photo: Sebastian Kaulitzki/Shutterstock)

Despite 30 years of failure on an evolving viral puzzle, there’s reason to believe we’ll one day live in a world without HIV.

It’s no secret that HIV is among the most devastating viruses plaguing humanity today. The World Health Organization puts the number of HIV deaths so far at more than 36 million people. Another 35 million are currently infected, including one in 20 adults in Sub-Saharan Africa. But don’t we know how to prevent viral infections? We have effective vaccines against many viruses. Why don’t we yet have one for HIV?

With an effective vaccine, we could make HIV join the ranks of formerly fearsome viruses that are now gone in most of the world—like the viruses that cause polio, smallpox, and measles. Considering the damage that viruses cause, an effective vaccine is a stunningly simple and reliable means of preventing death and suffering. When an effort to remove a bat colony from our home went wrong a few years ago, my family went to the clinic for our rabies shots—and then out for ice cream. We all slept well that night, knowing that, while rabies is fatal, it is also 100 percent preventable thanks to a vaccine. A vaccine that made HIV infections as preventable as rabies or polio would be one of the century’s greatest medical and humanitarian successes.

While we’ve been hearing promises about a vaccine for three decades, many recent insights into the immune escape mechanism of HIV result from the applications of new DNA analysis technology that has come online only within the past five years.

There is no effective HIV vaccine, but that’s not for lack of effort. After three decades of intense study, researchers have recognized that HIV presents challenges that are “unprecedented in the history of vaccinology.” Fortunately, there is reason for optimism. Within just the past five years, new biotechnologies have resulted in major breakthroughs in our understanding of HIV’s vulnerabilities. Before these recent developments, some researchers wondered whether an effective vaccine would ever be possible. Now, although a workable vaccine may not be exactly just around the corner, scientists have strong reasons to believe that we will eventually have one.

Most vaccines against viruses work by prompting our bodies to produce antibodies that latch on to and neutralize the virus. Figuring out where on the virus to target antibodies is a critical issue in the development of a vaccine. A vaccine is like the scrap of clothing investigators use to put a bloodhound on to a fugitive’s scent; by presenting specific viral fragments, a vaccine trains your body’s immune system to recognize the virus. A key challenge is to include the right viral parts in the vaccine, so that the immune system makes antibodies that effectively target and broadly neutralize all of the different mutational forms of HIV.

To be effective, an antibody has to target a part of the virus that is 1) critical to virus function and 2) easily accessible. Unfortunately, in the case of HIV, some critical parts of the virus are unusually well hidden and inaccessible to most antibodies. More importantly, many critically functional parts of the virus are hard to pin down. HIV is able to rapidly evolve new variations of important components in a nanoscale Houdini act called “mutational escape,” becoming a moving target for the immune system.

After several decades of little progress on a vaccine, many researchers had begun to doubt that broadly neutralizing, anti-HIV antibodies were possible. But in 2009, using new technologies to isolate and copy antibody-producing cells from HIV-infected patients, two groups of researchers discovered potent, broadly neutralizing antibodies. By showing that such antibodies exist, these studies gave researchers renewed hope that a vaccine against HIV is indeed feasible.

WITH THE DISCOVERY OF potent antibodies against HIV, researchers have been able to focus in on the details of how HIV evades the body’s defenses, with the aim of identifying new weak points that can be targeted by a vaccine. A study released in December, led by researchers at the National Institutes of Health Vaccine Research Center, identified a critical part of the virus that appears to play an important role in the mutational escape process. The researchers exposed vaccinated macaques to a mixture of different strains of the monkey version of HIV, Simian Immunodeficiency Virus (SIV). They found that a particular pair of mutations in SIV allowed the virus to evade vaccine-induced antibodies, and, remarkably, those mutations had the same effect on HIV. The researchers concluded that they had discovered signs of “a fundamental mechanism of immune escape.”

Discoveries like this will help researchers focus their vaccine-design efforts, especially in the aftermath of another failed HIV vaccine trial in 2013. It’s worth noting that, while we’ve been hearing promises about a vaccine for three decades, many recent insights into the immune escape mechanism of HIV result from the applications of new DNA analysis technology that has come online only within the past five years, and so we should stay optimistic.

Even without an effective HIV vaccine, worldwide public health efforts are making a dent in the death toll of HIV. Thanks to better therapies, more people are living with HIV, rather than dying from it. The heroic humanitarian efforts that have made these therapies available to nearly 10 million people deserve our admiration. But we shouldn’t give up our hope for a world in which HIV becomes a disease of the past, eliminated with a simple, inexpensive, but effective vaccine.

Michael White
Michael White is a systems biologist at the Department of Genetics and the Center for Genome Sciences and Systems Biology at the Washington University School of Medicine in St. Louis, where he studies how DNA encodes information for gene regulation. He co-founded the online science pub The Finch and Pea. Follow him on Twitter @genologos.

More From Michael White

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

October 24 • 4:00 PM

We Need to Normalize Drug Use in Our Society

After the disastrous misconceptions of the 20th century, we’re returning to the idea that drugs are an ordinary part of life experience and no more cause addiction than do other behaviors. This is rational and welcome.


October 24 • 2:00 PM

A Letter to the Next Attorney General: Fix Presidential Pardons

More than two years ago, a series showed that white applicants were far more likely to receive clemency than comparable applicants who were black. Since then, the government has spent hundreds of thousands of dollars on a study, but the pardons system remains unchanged.


October 24 • 12:00 PM

What Makes You So Smart, Middle School Math Teacher?

Noah Davis talks to Vern Williams about what makes middle school—yes, middle school—so great.


October 24 • 10:00 AM

Why DNA Is One of Humanity’s Greatest Inventions

How we’ve co-opted our genetic material to change our world.


October 24 • 8:00 AM

What Do Clowns Think of Clowns?

Three major players weigh in on the current state of the clown.


October 24 • 7:13 AM

There Is No Surge in Illegal Immigration

The overall rate of illegal immigration has actually decreased significantly in the last 10 years. The time is ripe for immigration reform.


October 24 • 6:15 AM

Politicians Really Aren’t Better Decision Makers

Politicians took part in a classic choice experiment but failed to do better than the rest of us.


October 24 • 5:00 AM

Why We Gossip: It’s Really All About Ourselves

New research from the Netherlands finds stories we hear about others help us determine how we’re doing.


October 24 • 2:00 AM

Congratulations, Your City Is Dying!

Don’t take population numbers at face value.


October 23 • 4:00 PM

Of Course Marijuana Addiction Exists

The polarized legalization debate leads to exaggerated claims and denials about pot’s potential harms. The truth lies somewhere in between.


October 23 • 2:00 PM

American Companies Are Getting Way Too Cozy With the National Security Agency

Newly released documents describe “contractual relationships” between the NSA and U.S. companies, as well as undercover operatives.


October 23 • 12:00 PM

The Man Who’s Quantifying New York City

Noah Davis talks to the proprietor of I Quant NY. His methodology: a little something called “addition.”


October 23 • 11:02 AM

Earliest High-Altitude Settlements Found in Peru

Discovery suggests humans adapted to high altitude faster than previously thought.


October 23 • 10:00 AM

The Psychology of Bribery and Corruption

An FBI agent offered up confidential information about a political operative’s enemy in exchange for cash—and they both got caught. What were they thinking?


October 23 • 8:00 AM

Ebola News Gives Me a Guilty Thrill. Am I Crazy?

What it means to feel a little excited about the prospect of a horrific event.


October 23 • 7:04 AM

Why Don’t Men Read Romance Novels?

A lot of men just don’t read fiction, and if they do, structural misogyny drives them away from the genre.


October 23 • 6:00 AM

Why Do Americans Pray?

It depends on how you ask.


October 23 • 4:00 AM

Musicians Are Better Multitaskers

New research from Canada finds trained musicians more efficiently switch from one mental task to another.


October 22 • 4:00 PM

The Last Thing the Women’s Movement Needs Is a Heroic Male Takeover

Is the United Nations’ #HeForShe campaign helping feminism?


October 22 • 2:00 PM

Turning Public Education Into Private Profits

Baker Mitchell is a politically connected North Carolina businessman who celebrates the power of the free market. Every year, millions of public education dollars flow through Mitchell’s chain of four non-profit charter schools to for-profit companies he controls.


October 22 • 12:00 PM

Will the End of a Tax Loophole Kill Off Irish Business and Force Google and Apple to Pay Up?

U.S. technology giants have constructed international offices in Dublin in order to take advantage of favorable tax policies that are now changing. But Ireland might have enough other draws to keep them there even when costs climb.


October 22 • 10:00 AM

Veterans in the Ivory Tower

Why there aren’t enough veterans at America’s top schools—and what some people are trying to do to change that.


October 22 • 8:00 AM

Our Language Prejudices Don’t Make No Sense

We should embrace the fact that there’s no single recipe for English. Making fun of people for replacing “ask” with “aks,” or for frequently using double negatives just makes you look like the unsophisticated one.


October 22 • 7:04 AM

My Politicians Are Better Looking Than Yours

A new study finds we judge the cover by the book—or at least the party.


October 22 • 6:00 AM

How We Form Our Routines

Whether it’s a morning cup of coffee or a glass of warm milk before bed, we all have our habitual processions. The way they become engrained, though, varies from person to person.


Follow us


Politicians Really Aren’t Better Decision Makers

Politicians took part in a classic choice experiment but failed to do better than the rest of us.

Earliest High-Altitude Settlements Found in Peru

Discovery suggests humans adapted to high altitude faster than previously thought.

My Politicians Are Better Looking Than Yours

A new study finds we judge the cover by the book—or at least the party.

That Cigarette Would Make a Great Water Filter

Clean out the ashtray, add some aluminum oxide, and you've (almost) got yourself a low-cost way to remove arsenic from drinking water.

Love and Hate in Israel and Palestine

Psychologists find that parties to a conflict think they're motivated by love while their enemies are motivated by hate.

The Big One

One company, Amazon, controls 67 percent of the e-book market in the United States—down from 90 percent five years ago. September/October 2014 new-big-one-5

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.